{
    "clinical_study": {
        "@rank": "89182", 
        "arm_group": {
            "arm_group_label": "Methylphenidate extended-release liquid", 
            "arm_group_type": "Experimental", 
            "description": "Methylphenidate extended-release liquid formulation"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether methylphenidate hydrochloride extended\n      release liquid formulation is safe and effective in the treatment of\n      attention-deficit/hyperactivity disorder (ADHD) in high-functioning adults with autism\n      spectrum disorders (ASD)."
        }, 
        "brief_title": "Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Attention-deficit/Hyperactivity Disorder", 
            "Autism Spectrum Disorder"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Autistic Disorder", 
                "Attention Deficit Disorder with Hyperactivity", 
                "Hyperkinesis", 
                "Child Development Disorders, Pervasive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female participants between 18 and 25 years of age (inclusive)\n\n          -  Fulfills Diagnostic and Statistical Manual 5 (DSM-5) diagnostic criteria for autism\n             spectrum disorder as established by the clinical diagnostic interview and Autism\n             Diagnostic Observation Schedule (ADOS)\n\n          -  Fulfills DSM-5 diagnostic criteria for Attention Deficit/Hyperactivity Disorder\n             (ADHD) as established by the clinical diagnostic interview and confirmed by the\n             Kiddie Schedule for Affective Disorders and Schizophrenia-Epidemiological Version\n             (K-SADS-E) ADHD module\n\n          -  Participants with at least moderately severe symptoms of Autism Spectrum Disorder\n             (ASD) as demonstrated by Social Responsiveness Scale (SRS) raw score greater than or\n             equal to 85 and Clinical Global Impression (CGI)-ASD severity score greater than or\n             equal to 4\n\n          -  Participants with at least moderately severe symptoms of ADHD as assessed by AISRS\n             score greater than or equal to 24 and CGI-ADHD severity score greater than or equal\n             to 4\n\n          -  Each participant must understand the nature of the study. The participant must sign\n             an Institutional Review Board-approved informed consent form before initiation of any\n             study procedures.\n\n          -  Participant must have a level of understanding sufficient to communicate with the\n             investigator and study coordinator, and to cooperate with all tests and examinations\n             required by the protocol.\n\n          -  Participant must be able to participate in mandatory blood draws.\n\n          -  Participant with major mood and/or anxiety disorders will be allowed to participate\n             in the study provided they do not meet any exclusionary criteria.\n\n        Exclusion Criteria:\n\n          -  Impaired intellectual capacity (Intelligence Quotient [IQ] less than 85; one standard\n             deviation below the mean IQ)\n\n          -  Participant is unable to communicate due to delay in, or total lack of, spoken\n             language development (grossly impaired language skills)\n\n          -  Clinically unstable psychiatric conditions or judged to be at serious safety risk to\n             self (suicidal risk) or others (within past 30 days).\n\n          -  Current diagnosis (within past 30 days) of an anxiety, mood, or psychotic disorder.\n\n          -  History of substance use (except nicotine or caffeine) within past 3 months\n             (inclusive) or with urine drug screen positive for substances of abuse\n\n          -  Subjects with a medical condition or treatment that will either jeopardize subject\n             safety or affect the scientific merit of the study, including:\n\n          -  Pregnant or nursing females or females with a positive urine pregnancy test.\n\n          -  Uncorrected hypothyroidism or hyperthyroidism.\n\n          -  History of non-febrile seizures within last 1 month without a clear and resolved\n             etiology.\n\n          -  History of renal or hepatic impairment.\n\n          -  Serious, unstable systemic illness\n\n          -  Personal history of cardiac disease or a family history of non-geriatric cardiac\n             disease or death\n\n          -  Clinically significant abnormal baseline laboratory values which include the\n             following: Values         more than 20% above the upper range of the laboratory\n             standard for a basic metabolic screen.\n\n          -  Systolic and diastolic blood pressure parameters above 140 and 90, respectively.\n\n          -  Resting heart rate outside of 60-100 beats per minute.\n\n          -  Abnormal electrocardiogram (ECG) parameters defined as a corrected QT interval\n             greater than 460 milliseconds, QRS interval greater than 120 milliseconds, and/or PR\n             interval greater than 200 milliseconds.\n\n          -  ECG evidence of ischemia or arrhythmia as reviewed by an independent cardiologist.\n\n          -  Participant with a history of non-response to adequate trial of methylphenidate\n             (therapeutic dose for an adequate duration) as determined by clinician.\n\n          -  History of intolerance or an allergic reaction to methylphenidate.\n\n          -  Current treatment with first- or second-generation antipsychotic medications or\n             stimulant class of anti-ADHD medications.\n\n          -  Current treatment with monoamine oxidase inhibitors (MAOIs)\n\n          -  Current treatment with a psychotropic medication on a dose that has not been stable\n             for at least 4 weeks prior to baseline visit.\n\n          -  Investigator and his/her immediate family, defined as the investigator's spouse,\n             parent, child, grandparent, or grandchild."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "25 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02096952", 
            "org_study_id": "2014P000501"
        }, 
        "intervention": {
            "arm_group_label": "Methylphenidate extended-release liquid", 
            "intervention_name": "Methylphenidate extended-release liquid formulation", 
            "intervention_type": "Drug", 
            "other_name": [
                "Methylphenidate extended-release liquid formulation", 
                "Quillivant extended release"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Methylphenidate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Attention-deficit/hyperactivity disorder", 
            "ADHD", 
            "Autism spectrum disorder", 
            "ASD", 
            "High-functioning ASD", 
            "Asperger's disorder", 
            "Asperger's"
        ], 
        "lastchanged_date": "March 25, 2014", 
        "location": {
            "contact": {
                "email": "sfurtak1@mgh.harvard.edu", 
                "last_name": "Stephannie Furtak", 
                "phone": "617-724-2344"
            }, 
            "contact_backup": {
                "email": "rgrossman1@mgh.harvard.edu", 
                "last_name": "Rebecca Grossman", 
                "phone": "617-643-1432"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02144"
                }, 
                "name": "Massachusetts General Hospital"
            }, 
            "investigator": {
                "last_name": "Gagan Joshi, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Open-Label Treatment Trial to Assess the Short-Term Tolerability, Safety, and Efficacy of Methylphenidate Hydrochloride Extended-Release Liquid Formulation in High-Functioning Autism Spectrum Disorder Adults With Attention-Deficit/Hyperactivity Disorder", 
        "overall_contact": {
            "email": "sfurtak1@mgh.harvard.edu", 
            "last_name": "Stephannie Furtak", 
            "phone": "617-724-2344"
        }, 
        "overall_contact_backup": {
            "email": "rgrossman1@mgh.harvard.edu", 
            "last_name": "Rebecca Grossman", 
            "phone": "617-643-1432"
        }, 
        "overall_official": {
            "affiliation": "Massachusetts General Hospital", 
            "last_name": "Gagan Joshi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The Adult ADHD Investigator Symptom Report Scale (AISRS) assesses each of the 18 individual symptoms of ADHD in DSM-IV on a Likert scale from 0 (not present) to 3 (severe), with a total possible score of 54.", 
            "measure": "Adult ADHD Investigator Symptom Report Scale (AISRS)", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02096952"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Massachusetts General Hospital", 
            "investigator_full_name": "Gagan Joshi, MD", 
            "investigator_title": "Assistant professor of Psychiatry, Harvard Medical School; Director, Autism Spectrum Disorder Clinical & Research Program, Pediatric Psychopharmacology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Massachusetts General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Massachusetts General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}